Diagnosis of sepsis

• US 7,767,395 B2
• Filed: 04/14/2006
• Issued: 08/03/2010
• Est. Priority Date: 04/15/2005
• Status: Active Grant

• Current Assignee: Becton, Dickinson & Co
• Original Assignee: Becton, Dickinson & Co
• Inventors: Thornton, Keith, Whiteford, Craig C., Wang, Sha-Sha, Nussbaumer, William A., Garrett, James A., Keating, William, Moore, Richard L.
• Primary Examiner(s): KAPUSHOC, STEPHEN THOMAS
• Application Number:
  US11/404,744
• Publication Number:
  US 20060246495A1
• Time in Patent Office: 1,572 Days
• Field of Search: None
• US Class Current: 435/6.18
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 1/6888 for detection or identification of organisms
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays
• CPC Class Codes: G01N 2333/5412 IL-6
• CPC Class Codes: G01N 2333/5421 IL-8
• CPC Class Codes: G01N 2800/26 Infectious diseases, e.g. generalised sepsis
• CPC Class Codes: G01N 2800/50 Determining the risk of developing a disease
• CPC Class Codes: G01N 33/56911 Bacteria
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.

Claims

1. A method of predicting an increased likelihood of developing sepsis in a human SIRS patient comprising:

obtaining a first blood sample from said patient, said sample comprising biomarker mRNAs;

measuring the abundances of said biomarker mRNAs in said first blood sample taken from said patient, wherein said biomarker mRNAs comprise TRAF-interacting protein with a forkhead-associated domain (TIFA) mRNA, growth arrest and DNA damage-inducible gene (GADD45B) mRNA, major histocompatibility complex, class II, DR alpha (HLA-DRA) mRNA, carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) mRNA, oncostatin M (OSM) mRNA, and arginase, type II (ARG2) mRNA; and

comparing said abundances of said biomarker mRNAs in said first blood sample to abundances of said biomarker mRNAs in (i) blood samples taken 0-36 hours prior to sepsis development in a SIRS-positive human patient population that progresses to sepsis, and (ii) blood samples taken from a SIRS-positive human patient population that does not progress to sepsis;

wherein an increased likelihood of developing sepsis is predicted in the SIRS patient when it is determined that the biomarker mRNA abundances in the first blood sample are statistically significantly similar to the biomarker mRNA abundances in the blood samples taken from the SIRS-positive human patient population that progresses to sepsis;

wherein a decreased likelihood of developing sepsis is predicted in the SIRS patient when it is determined that the mRNA abundances in the first blood sample are statistically significantly similar to the mRNA abundances in the blood samples taken from the SIRS-positive human patient population that does not progress to sepsis; and

wherein said SIRS-positive human patient population that progresses to sepsis and said SIRS-positive human patient human population that does not progress to sepsis each comprises at least 20 individuals.

2. The method of claim 1, wherein said first blood sample is a whole blood sample or a plasma sample.

3. The method of claim 1, wherein the abundances of said biomarker mRNAs are expressed in relative fluorescence intensity units.

4. The method of claim 1, wherein the measuring step comprises performing reverse-transcription-polymerase chain reaction to make cDNA complimentary to said biomarker RNAs.

5. The method of claim 1, wherein the measuring step comprises contacting said biomarker mRNAs, or cDNAs thereof, to a nucleic acid array.

6. The method of claim 1, wherein the comparing step comprises applying a decision rule to predict the increased or decreased likelihood of sepsis in the SIRS patient.

7. The method of claim 1, wherein the comparing step is performed on a computer.